Bilaketaren emaitzak - Marc‐Eric Halatsch

Findu emaitzak
  1. 1
    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide

    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous... nork Richard E. Kast, Georg Karpel‐Massler, Marc‐Eric Halatsch

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

    Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? nork Georg Karpel‐Massler, Ursula Schmidt, Andreas Unterberg, Marc‐Eric Halatsch

    Argitaratua 2009
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

    Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma nork Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Markus D. Siegelin

    Argitaratua 2017
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

    BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma nork Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells

    Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells nork Joachim Bischof, Mike‐Andrew Westhoff, Johanna Wagner, Marc‐Eric Halatsch, Stephanie Trentmann, Uwe Knippschild, Christian Rainer Wirtz, Timo Burster

    Argitaratua 2017
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin

    Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin nork Richard E. Kast, Quentin A. Hill, Didier Wion, Håkan Mellstedt, Daniele Focosi, Georg Karpel‐Massler, Tim Heiland, Marc‐Eric Halatsch

    Argitaratua 2017
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i>

    TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i> nork Georg Karpel‐Massler, Maïmouna Bâ, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i>

    Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i> nork Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    RIST: A potent new combination therapy for glioblastoma

    RIST: A potent new combination therapy for glioblastoma nork Lisa Nonnenmacher, Mike‐Andrew Westhoff, Simone Fulda, Georg Karpel‐Massler, Marc‐Eric Halatsch, Jens Engelke, Thomas Simmet, Selim Corbacioglu, Klaus‐Michael Debatin

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i>

    Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> nork Georg Karpel‐Massler, Matei A. Banu, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy

    A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy nork Stephanie Ströbele, Matthias Schneider, Lukas Schneele, Markus D. Siegelin, Lisa Nonnenmacher, Shaoxia Zhou, Georg Karpel-Massle, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Klaus‐Michael Debatin

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

    Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells nork Georg Karpel‐Massler, Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Annika Dwucet, Richard E. Kast, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin, Marc‐Eric Halatsch

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    The effects of PI3K-mediated signalling on glioblastoma cell behaviour

    The effects of PI3K-mediated signalling on glioblastoma cell behaviour nork Julia Langhans, Lukas Schneele, Nancy Trenkler, Hélène von Bandemer, Lisa Nonnenmacher, Georg Karpel‐Massler, Markus D. Siegelin, Shaoxia Zhou, Marc‐Eric Halatsch, Klaus‐Michael Debatin, Mike‐Andrew Westhoff

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma

    Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma nork Maximilian Pruss, Annika Dwucet, Mine Tanriover, Michal Hlaváč, Richard E. Kast, Klaus‐Michael Debatin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Markus D. Siegelin, Mike‐Andrew Westhoff, Georg Karpel‐Massler

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i>

    Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> nork Georg Karpel‐Massler, Chang Shu, Lily Chau, Matei A. Banu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Yulian P. Ramirez, Alonzo H. Ross, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro

    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro nork Qiyu Cao, Annika Hajosch, Richard E. Kast, Christopher Loehmann, Michal Hlaváč, Pamela Fischer‐Posovszky, Hannah A. Strobel, Mike‐Andrew Westhoff, Markus D. Siegelin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Georg Karpel‐Massler

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    A paired comparison between glioblastoma “stem cells” and differentiated cells

    A paired comparison between glioblastoma “stem cells” and differentiated cells nork Matthias Schneider, Stephanie Ströbele, Lisa Nonnenmacher, Markus D. Siegelin, Melanie Tepper, Sebastien Stroh, Sebastian Hasslacher, Stefanie Enzenmüller, Gudrun Strauß, Bernd Baumann, Georg Karpel‐Massler, Mike‐Andrew Westhoff, Klaus‐Michael Debatin, Marc‐Eric Halatsch

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma

    Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma nork Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Georg Karpel‐Massler, Claudia Jennewein, Matthias Schneider, Marc‐Eric Halatsch, Neil O. Carragher, Bernd Baumann, Alexander Krause, Thomas Simmet, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Phosphoinositide 3-Kinases Upregulate System x<sub>c</sub><sup>−</sup> <i>via</i> Eukaryotic Initiation Factor 2α and Activating Transcription Factor 4 – A Pathway Active in Glioblastomas and Epilepsy

    Phosphoinositide 3-Kinases Upregulate System x<sub>c</sub><sup>−</sup> <i>via</i> Eukaryotic Initiation Factor 2α and Activating Transcription Factor 4 – A Pathway Active in Gliobl... nork Jan Lewerenz, Paul Baxter, Rebecca Kassubek, Philipp Albrecht, Joeri Van Liefferinge, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Georg Karpel‐Massler, Paul J. Meakin, John D. Hayes, Eleonora Aronica, Ilse Smolders, Albert C. Ludolph, Axel Methner, Marcus Conrad, Ann Massie, Giles E. Hardingham, Pamela Maher

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 nork Marc‐Eric Halatsch, Richard E. Kast, Georg Karpel‐Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer‐Steinacker, Carl J. Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike‐Andrew Westhoff, Kristine Beckers, Gauthier Bouche, Tim Heiland

    Argitaratua 2021
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: